{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:48:03Z","timestamp":1792018083923,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate whether the use of proprotein convertase subtilisin\/kexin type 9 inhibitors (PCSK9is) is associated with a reduced 1-year incidence of new-onset heart failure (HF) compared to statins among patients with dyslipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study using the TriNetX global health research network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the TriNetX global health research network. Adults diagnosed with dyslipidemia and initiated on either PCSK9is or statins between 2015 and 2025 were included. One-to-one propensity score matching (PSM) was applied to balance baseline characteristics. The primary outcome was new-onset HF within 1 year. Cox proportional hazards models were used to estimate hazard ratios (HRs), with E-values calculated to assess unmeasured confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSM, 40\u00a0098 patients were included in each group. The incidence of new-onset HF was significantly lower in the PCSK9is group (1.8 vs. 2.7 per 100 person-years [PYs]; HR 0.69; 95% CI, 0.63\u20130.76; P &amp;lt; 0.001). Subgroup analyses confirmed consistent benefit across age, sex, and comorbidity strata. Secondary outcomes including all-cause mortality, hospitalization, and MACEs were also significantly reduced in the PCSK9is group. A negative control outcome showed no significant association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with dyslipidemia, PCSK9i use was associated with a significantly lower 1-year risk of new-onset HF and improved secondary outcomes compared to statin therapy. These findings support a potential preventive role of PCSK9is in HF, warranting further prospective studies to confirm these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/qjmed\/hcag235","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:53:34Z","timestamp":1788954814000},"source":"Crossref","is-referenced-by-count":2,"title":["Association between PCSK9 inhibitor use and risk of incident heart failure in patients with dyslipidemia"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng-Yan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Nutrition, Chi Mei Medical Center , Tainan,","place":["Taiwan"]},{"name":"Department of Public Health, College of Medicine, National Cheng Kung University , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Wei","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chi Mei Hospital, Chiali , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Chi Mei Medical Center , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Yuan","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Chi Mei Medical Centre , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1723-828X","authenticated-orcid":false,"given":"Yu-Min","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"2026092703114288900_hcag235-B1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026092703114288900_hcag235-B2","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ Res"},{"key":"2026092703114288900_hcag235-B3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026092703114288900_hcag235-B4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","article-title":"Global epidemiology of dyslipidaemias","volume":"18","author":"Pirillo","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2026092703114288900_hcag235-B5","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/j.jacc.2020.03.072","article-title":"Small dense low-density lipoprotein cholesterol predicts atherosclerotic cardiovascular disease in the copenhagen general population study","volume":"75","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026092703114288900_hcag235-B6","first-page":"312","article-title":"Left ventricular geometry and arterial function in hypercholesterolemia","volume":"11","author":"Celentano","year":"2001","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026092703114288900_hcag235-B7","first-page":"2860","article-title":"Dyslipidemia and heart failure: current evidence and perspectives of use of statins","volume":"28","author":"Pradhan","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026092703114288900_hcag235-B8","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of Scotland coronary prevention study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"key":"2026092703114288900_hcag235-B9","doi-asserted-by":"crossref","first-page":"e14400","DOI":"10.1097\/MD.0000000000014400","article-title":"Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: a frequentist network meta-analysis","volume":"98","author":"Zhao","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2026092703114288900_hcag235-B10","doi-asserted-by":"crossref","first-page":"10742484221100107","DOI":"10.1177\/10742484221100107","article-title":"A comprehensive review of PCSK9 inhibitors","volume":"27","author":"Coppinger","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026092703114288900_hcag235-B11","doi-asserted-by":"crossref","first-page":"114106","DOI":"10.1016\/j.biopha.2022.114106","article-title":"PCSK9: an emerging participant in heart failure","volume":"158","author":"Xu","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026092703114288900_hcag235-B12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10741-024-10409-7","article-title":"The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol","volume":"29","author":"Dutka","year":"2024","journal-title":"Heart Fail Rev"},{"key":"2026092703114288900_hcag235-B13","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2017.08.057","article-title":"The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis","volume":"70","author":"Bayes-Genis","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026092703114288900_hcag235-B14","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"2026092703114288900_hcag235-B15","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"key":"2026092703114288900_hcag235-B16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the e-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026092703114288900_hcag235-B17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4093\/dmj.2024.0066","article-title":"Different associations between lipid levels and risk for heart failure according to diabetes progression","volume":"49","author":"Lee","year":"2025","journal-title":"Diabetes Metab J"},{"key":"2026092703114288900_hcag235-B18","doi-asserted-by":"crossref","first-page":"e032378","DOI":"10.1161\/JAHA.123.032378","article-title":"Statin therapy is associated with a lower risk of heart failure in patients with atrial fibrillation: a population-based study","volume":"12","author":"Huang","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026092703114288900_hcag235-B19","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study","volume":"47","author":"Scirica","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026092703114288900_hcag235-B20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026092703114288900_hcag235-B21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"Chapman","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"2026092703114288900_hcag235-B22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.15420\/ecr.2018.3.2","article-title":"Management of severe dyslipidaemia: role of PCSK9 inhibitors","volume":"13","author":"Nicholls","year":"2018","journal-title":"Eur Cardiol"},{"key":"2026092703114288900_hcag235-B23","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1111\/jcmm.14586","article-title":"PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia\/reperfusion injury: benefits beyond lipid-lowering effects","volume":"23","author":"Palee","year":"2019","journal-title":"J Cell Mol Med"},{"key":"2026092703114288900_hcag235-B24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1046\/j.1365-2362.1999.00481.x","article-title":"Cardiomyocyte apoptosis and progression of heart failure to transplantation","volume":"29","author":"Saraste","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"2026092703114288900_hcag235-B25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4149\/gpb_2019057","article-title":"PCSK9 promotes the secretion of pro-inflammatory cytokines by macrophages to aggravate H\/R-induced cardiomyocyte injury via activating NF-\u03baB signalling","volume":"39","author":"Yang","year":"2020","journal-title":"Gen Physiol Biophys"},{"key":"2026092703114288900_hcag235-B26","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/ATVBAHA.111.224907","article-title":"Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease","volume":"31","author":"Zheng","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026092703114288900_hcag235-B27","doi-asserted-by":"crossref","first-page":"809806","DOI":"10.3389\/fimmu.2021.809806","article-title":"Apoptosis, autophagy, NETosis, necroptosis, and pyroptosis mediated programmed cell death as targets for innovative therapy in rheumatoid arthritis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"2026092703114288900_hcag235-B28","doi-asserted-by":"crossref","first-page":"101523","DOI":"10.1016\/j.redox.2020.101523","article-title":"NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy","volume":"34","author":"Zeng","year":"2020","journal-title":"Redox Biol"},{"key":"2026092703114288900_hcag235-B29","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/cvr\/cvy128","article-title":"PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2026092703114288900_hcag235-B30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026092703114288900_hcag235-B31","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1","volume":"116","author":"Ding","year":"2020","journal-title":"Cardiovasc Res"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcag235\/71019375\/hcag235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcag235\/71019375\/hcag235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:11:52Z","timestamp":1790493112000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article\/doi\/10.1093\/qjmed\/hcag235\/8789999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcag235","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"hcag235"}}